Attendee search 

Business Region Göteborg AB is dedicated to strengthening and developing trade and industry in the Göteborg region in West Sweden. Our goal is to contribute to sustainable economic growth, a high level of employment and a diversified economy. The department of Business Establishment and Investment at Business Region Gothenburg is a “one-stop-shop, which aims at simplifying and assisting all companies planning to invest, relocate to or expand its operations in West Sweden.

Business Region Gothenburg is the first port of call for foreign companies or organisations looking for licensing opportunities, R&D collaboration, technology access, feasibility studies, potential partners and investment opportunities in West Sweden. Furthermore, We identify business opportunities abroad for our key accounts in West Sweden’s Life Science cluster which include but are not limited to research Institutes, Life Science companies, Science parks and incubators.

By getting in contact with us you will receive all information from a single player. We will also establish the necessary contacts and help you from introduction to business case. All our services are free-of-charge. We also help in booking meetings, site visits and finding premises if needed for entering the Scandinavian market.

Redoxis is a Swedish company which main competence is target validation and preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA) and multiple sclerosis (MS) and we have several years of expertise of animal models for these diseases. We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo in animal models and we can assist in design, performance and interpretation of the results from the experiments. Our model systems are well validated and as a small company can offer flexible study design through communication with our sponsors. 

Redoxis drug development project is characterized by protected small molecules targeting target of immunological relevance that are regulated by Redoxis stimulation and of importance in CD4 T cell receptor signaling immune responses. Of primary focus are autoimmune disorders like the orphan disease Guillain-Barrés Syndrome (GBS), Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA).

Mevia develops intelligent pharmaceutical solutions to support patient adherence and increase the quality of drug treatments. With our innovative technology, each medical event is automatically registered and if a dose is forgotten the patient can immediately recieve a reminder. Our service enables closer contact between patients, healthcare and relatives.